Khalbuss, W. E., Laucirica, R. & Pantanowitz, L. in Cytopathology of Infectious Diseases Vol. 17 (ed. Rosenthal, D. L.) 121–159 (Springer, 2011).
Gorbalenya, A. E. et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544 (2020).
Wang, H. et al. Modelling the economic burden of SARS-CoV-2 infection in health care workers in four countries. Nat. Commun. 14, 2791 (2023).
Serrano-Ripoll, M. J. et al. Impact of viral epidemic outbreaks on mental health of healthcare workers: a rapid systematic review and meta-analysis. J. Affect. Disord. 277, 347–357 (2020).
Torres Munguía, J. A., Badarau, F. C., Díaz Pavez, L. R., Martínez-Zarzoso, I. & Wacker, K. M. A global dataset of pandemic- and epidemic-prone disease outbreaks. Sci. Data 9, 683 (2022).
Sampath, S. et al. Pandemics throughout the history. Cureus 13, e18136 (2021).
Miller, I. F., Becker, A. D., Grenfell, B. T. & Metcalf, C. J. E. Disease and healthcare burden of COVID-19 in the United States. Nat. Med. 26, 1212–1217 (2020).
Short, K. R., Kroeze, E. J. B. V., Fouchier, R. A. M. & Kuiken, T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect. Dis. 14, 57–69 (2014).
Torres Acosta, M. A. & Singer, B. D. Pathogenesis of COVID-19-induced ARDS: implications for an ageing population. Eur. Clin. Respir. J. 56, 2002049 (2020).
Luyt, C.-É., Combes, A., Trouillet, J.-L., Nieszkowska, A. & Chastre, J. Virus-induced acute respiratory distress syndrome: epidemiology, management and outcome. Presse Med. 40, e561–e568 (2011).
Krynytska, I., Marushchak, M., Birchenko, I., Dovgalyuk, A. & Tokarskyy, O. COVID-19-associated acute respiratory distress syndrome versus classical acute respiratory distress syndrome (a narrative review). Iran. J. Microbiol. 13, 737–747 (2021).
Xia, B. et al. SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target. Cell Res. 31, 847–860 (2021).
Liu, J. et al. SARS-CoV-2 cell tropism and multiorgan infection. Cell Discov. 7, 17 (2021).
Mokhtari, T. et al. COVID-19 and multiorgan failure: a narrative review on potential mechanisms. J. Mol. Histol. 51, 613–628 (2020).
Novak, T. et al. Transcriptomic profiles of multiple organ dysfunction syndrome phenotypes in pediatric critical influenza. Front. Immunol. 14, 1220028 (2023).
Tang, B. M., Cootes, T. & McLean, A. S. in Annual Update in Intensive Care and Emergency Medicine 2019 (ed. Vincent, J.-L.) 449–458 (Springer, 2019).
Diamond, M. S. & Kanneganti, T.-D. Innate immunity: the first line of defense against SARS-CoV-2. Nat. Immunol. 23, 165–176 (2022).
Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805–820 (2010).
Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786–791 (2013).
Melchjorsen, J., Sørensen, L. N. & Paludan, S. R. Expression and function of chemokines during viral infections: from molecular mechanisms to in vivo function. J. Leukoc. Biol. 74, 331–343 (2003).
Khalil, B. A., Elemam, N. M. & Maghazachi, A. A. Chemokines and chemokine receptors during COVID-19 infection. Comput. Struct. Biotechnol. J. 19, 976–988 (2021).
Kasuga, Y., Zhu, B., Jang, K.-J. & Yoo, J.-S. Innate immune sensing of coronavirus and viral evasion strategies. Exp. Mol. Med. 53, 723–736 (2021).
Chen, X. et al. Host immune response to influenza A virus infection. Front. Immunol. 9, 320 (2018).
Kim, Y.-M. & Shin, E.-C. Type I and III interferon responses in SARS-CoV-2 infection. Exp. Mol. Med. 53, 750–760 (2021).
Alfi, O. et al. Human nasal and lung tissues infected ex vivo with SARS-CoV-2 provide insights into differential tissue-specific and virus-specific innate immune responses in the upper and lower respiratory tract. J. Virol. 95, e0013021 (2021).
Prasad, M. et al. Viral endothelial dysfunction: a unifying mechanism for COVID-19. Mayo Clin. Proc. 96, 3099–3108 (2021).
Gluck, J. P. & Bell, J. Ethical issues in the use of animals in biomedical and psychopharmocological research. Psychopharmacology 171, 6–12 (2003).
Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 110, 3507–3512 (2013).
Thacker, V. V. et al. Rapid endotheliitis and vascular damage characterize SARS‐CoV‐2 infection in a human lung‐on‐chip model. EMBO Rep. 22, e52744 (2021).
Zhang, M. et al. Biomimetic human disease model of SARS‐CoV‐2‐induced lung injury and immune responses on organ chip system. Adv. Sci. 8, 2002928 (2021).
Bai, H. et al. Mechanical control of innate immune responses against viral infection revealed in a human lung alveolus chip. Nat. Commun. 13, 1928 (2022).
Si, L. et al. A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. Nat. Biomed. Eng. 5, 815–829 (2021).
Marx, V. Cell-line authentication demystified. Nat. Methods 11, 483–488 (2014).
Beers, M. F. & Moodley, Y. When is an alveolar type 2 cell an alveolar type 2 cell? A conundrum for lung stem cell biology and regenerative medicine. Am. J. Respir. Cell Mol. Biol. 57, 18–27 (2017).
Ortiz, M. E. et al. Heterogeneous expression of the SARS-coronavirus-2 receptor ACE2 in the human respiratory tract. EBioMedicine 60, 102976 (2020).
Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036–1045.e9 (2020).
Kocherova, I. et al. Human umbilical vein endothelial cells (HUVECs) co-culture with osteogenic cells: from molecular communication to engineering prevascularised bone grafts. J. Clin. Med. 8, 1602 (2019).
Fujimoto, K. et al. SARS-CoV-2-induced disruption of a vascular bed in a microphysiological system caused by type-I interferon from bronchial organoids. Lab Chip 24, 3863–3879 (2024).
Konishi, S. et al. Directed induction of functional multi-ciliated cells in proximal airway epithelial spheroids from human pluripotent stem cells. Stem Cell Rep. 6, 18–25 (2016).
Rawlins, E. L., Ostrowski, L. E., Randell, S. H. & Hogan, B. L. M. Lung development and repair: contribution of the ciliated lineage. Proc. Natl Acad. Sci. USA 104, 410–417 (2007).
You, Y. et al. Role of f-box factor foxj1 in differentiation of ciliated airway epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 286, L650–L657 (2004).
Zarbock, R. et al. The surfactant protein C mutation A116D alters cellular processing, stress tolerance, surfactant lipid composition, and immune cell activation. BMC Pulm. Med. 12, 15 (2012).
Gotoh, S. et al. Generation of alveolar epithelial spheroids via isolated progenitor cells from human pluripotent stem cells. Stem Cell Rep. 3, 394–403 (2014).
Daly, J. L. et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science 370, 861–865 (2020).
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020).
Hashimoto, R. et al. SARS-CoV-2 disrupts respiratory vascular barriers by suppressing claudin-5 expression. Sci. Adv. 8, eabo6783 (2022).
Nascimento Conde, J., Schutt, W. R., Gorbunova, E. E. & Mackow, E. R. Recombinant ACE2 expression is required for SARS-CoV-2 to infect primary human endothelial cells and induce inflammatory and procoagulative responses. mBio 11, e03185-20 (2020).
Monk, P. D. et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir. Med. 9, 196–206 (2021).
Ahn, J. H. et al. Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19. J. Clin. Invest. 131, e148517 (2021).
Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 182, 429–446.e14 (2020).
Kobayashi, Y. et al. Persistence of a regeneration-associated, transitional alveolar epithelial cell state in pulmonary fibrosis. Nat. Cell Biol. 22, 934–946 (2020).
Weng, A. et al. Lung injury induces alveolar type 2 cell hypertrophy and polyploidy with implications for repair and regeneration. Am. J. Respir. Cell Mol. Biol. 66, 564–576 (2022).
Ting, C. et al. Fatal COVID-19 and non–COVID-19 acute respiratory distress syndrome is associated with incomplete alveolar type 1 epithelial cell differentiation from the transitional state without fibrosis. Am. J. Pathol. 192, 454–467 (2022).
Galani, I. E. et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat. Immunol. 22, 32–40 (2021).
Carrat, F. et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am. J. Epidemiol. 167, 775–785 (2008).
Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718–724 (2020).
Schimmel, L. et al. Endothelial cells are not productively infected by SARS‐CoV‐2. Clin. Transl. Immunol. 10, e1350 (2021).
Yamamoto, Y. et al. Long-term expansion of alveolar stem cells derived from human iPS cells in organoids. Nat. Methods 14, 1097–1106 (2017).
Sherman, B. T. et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 50, W216–W221 (2022).
Oliveros, J. C. Venny. An interactive tool for comparing lists with Venn’s diagrams. https://bioinfogp.cnb.csic.es/tools/venny/index.html (2007–2015).
Yadav, S. et al. Isogenic iPSC-derived proximal and distal lung-on-chip models reveal tissue and virus-specific immune responses in human lungs. NCBI GEO (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE247677).
